Bioatla 2025 Q3 Earnings Net Loss Widens 49% to $15.8M

Bioatla’s Q3 2025 results missed expectations, with a 49% wider net loss compared to the prior year. The company reported no revenue, a stark decline from $11 million in Q3 2024. Despite strategic advancements, financial performance remains challenging, with no guidance adjustments announced.

Revenue

Bioatla reported $0 in Q3 2025 revenue, a 100% decline from $11 million in Q3 2024. The absence of collaboration revenue and the absence of new product sales contributed to the sharp drop.

Earnings/Net Income

The company’s net loss widened to $15.78 million (EPS -$0.27) in Q3 2025, a 49% increase from $10.59 million (EPS -$0.22) in Q3 2024. The EPS reflects a significant deterioration in profitability amid ongoing operational challenges.

Price Action

Bioatla’s stock price declined 1.54% on the latest trading day, gained 3.03% over the past week, but fell 17.63% month-to-date. The mixed short-term performance underscores market uncertainty around the company’s financial health.

Post-Earnings Price Action Review

The strategy of buying Bioatla shares on earnings release dates and holding for 30 days generated a 1.61% return over three years. This approach leverages the company’s predictable earnings schedule to capture short-term volatility. However, the modest returns suggest limited upside, as Bioatla’s financial struggles—such as a 49% wider net loss in Q3 2025—outweigh near-term optimism. The strategy’s appeal lies in its low-risk profile, but investors must weigh it against the company’s sustained losses and uncertain growth trajectory.

CEO Commentary

CEO Jay Short highlighted progress in FDA-aligned phase 3 trial designs for Oz-V in OPSCC and partnerships in the Dual-CAB EpCAM TCE program. He emphasized 2026 milestones, including Phase III trial initiation and key clinical readouts, as catalysts for shareholder value.

Guidance

Bioatla expects reduced R&D and G&A expenses through 2025, driven by workforce optimization and resource prioritization. The company aims to secure strategic partnerships by year-end to accelerate development and fund its pipeline.

Additional News

1. FDA Alignment: Bioatla secured FDA approval for its phase 3 Oz-V trial in OPSCC, with dual endpoints for potential accelerated approval.

2. Milestone Payment: A $2 million non-dilutive payment from Context Therapeutics for the Dual-CAB Nectin-4 TCE program bolstered cash reserves.

3. Clinical Progress: Promising Phase 1 data for BA3182, including a confirmed partial response in cholangiocarcinoma, were presented at ESMO 2025.